BMED - ETF AI Analysis

Top Page

Future Health ETF (BMED)

Rating:64Neutral

Price Target:―

BMED, the Future Health ETF, has a solid overall rating driven by strong, diversified holdings in major healthcare leaders like Medtronic, Merck, Johnson & Johnson, and Gilead, which benefit from healthy financial performance, promising pipelines, and supportive earnings calls. These strengths are partly offset by weaker names such as Moderna and Guardant Health, where financial instability, declining revenues, and valuation concerns introduce more uncertainty. The main risk factor is exposure to several companies with profitability and valuation challenges, which could add volatility even though the overall portfolio is anchored by more stable blue-chip healthcare firms.

Positive Factors

Strong Recent Performance

The ETF has shown solid gains over the past three months and year-to-date, indicating positive recent momentum.

Leading Health Care Holdings

Several top positions, including well-known global health care companies, have delivered strong or steady performance that supports the fund.

Global Health Care Exposure

While focused on the U.S., the fund also holds meaningful positions in major international markets like Switzerland, Germany, and Japan, adding some geographic diversification.

Negative Factors

High Sector Concentration

With the vast majority of assets in health care, the ETF is heavily exposed to risks specific to that single sector.

Moderately High Expense Ratio

The fund’s expense ratio is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.

Small Asset Base

The relatively low level of assets under management may lead to lower trading volume and potentially wider bid-ask spreads for investors.

BMED vs. SPDR S&P 500 ETF (SPY)

AUM10.00M

RegionGlobal

Expense Ratio0.55%

Beta0.71

IssueriShares

Inception DateSep 29, 2020

Dividend YieldN/A

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume11,677

30 Day Avg. Volume4,895

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

37.10

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering138

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

BMED Summary

The Future Health ETF (BMED) focuses on the health care theme, investing in companies working on new drugs, medical devices, and advanced health services, mainly in the U.S. It does not track a traditional index, but instead selects a mix of established names and innovators. Well-known holdings include Johnson & Johnson and Merck. Someone might invest in BMED to seek long-term growth from medical breakthroughs while spreading risk across many health care companies. A key risk is that it is heavily concentrated in the health care sector, so its price can rise or fall sharply with changes in that industry.

How much will it cost me?The Future Health ETF (Ticker: BMED) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like health care innovation, which typically requires more research and management expertise.

What would affect this ETF?The Future Health ETF (BMED) could benefit from ongoing advancements in biotechnology and medical devices, as well as increased global demand for innovative health care solutions. However, it may face challenges from regulatory changes in the health care sector or economic downturns that reduce funding for medical innovation. Its global exposure and focus on leading companies like Abbott Laboratories and Johnson & Johnson provide stability but also make it sensitive to international market conditions.

BMED Top 10 Holdings

BMED is firmly hitched to the future of health care, with a global mix of big drugmakers and fast-moving innovators steering returns. Established giants like Roche, Johnson & Johnson, and Merck are rising steadily, providing the fund with a solid, defensive backbone. On the growth side, Guardant Health, Exact Sciences, and Moderna have been sprinting higher lately, giving the ETF much of its recent spark, even if their finances are still a bit wobbly. Overall, the fund is concentrated in health care, not any single stock, and leans into innovation without abandoning stability.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
JNJ	Johnson & Johnson	3.55%	$354.80K	$547.51B	49.36%	78 Outperform
GILD	Gilead Sciences	3.01%	$300.73K	$176.11B	46.04%	78 Outperform
EXAS	Exact Sciences	2.92%	$292.27K	$19.53B	82.59%	70 Outperform
MDT	Medtronic	2.85%	$284.62K	$132.00B	13.37%	80 Outperform
GH	Guardant Health	2.64%	$264.27K	$14.75B	142.74%	61 Neutral
ROG	Roche Holding AG	2.61%	$260.87K	CHF279.83B	41.58%	73 Outperform
MRK	Merck & Company	2.60%	$260.23K	$273.69B	11.59%	80 Outperform
EW	Edwards Lifesciences	2.45%	$245.12K	$47.21B	12.30%	79 Outperform
MRNA	Moderna	2.34%	$233.78K	$17.22B	11.80%	59 Neutral
NOVN	Novartis AG	2.12%	$211.74K	CHF218.15B	19.92%	80 Outperform

BMED Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price―

Price Trends

50DMA

30.71

Positive

100DMA

29.17

Positive

200DMA

26.93

Positive

Market Momentum

MACD

0.25

Positive

RSI

49.67

Neutral

STOCH

31.80

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BMED, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 31.28, equal to the 50-day MA of 30.71, and equal to the 200-day MA of 26.93, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 31.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMED.

BMED Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
BMED	―	―	$10.00M	0.55%	―
FMED	―	―	$63.28M	0.50%	―
MEDI	―	―	$26.53M	0.80%	―
MEDX	―	―	$19.05M	0.85%	―
TMED	―	―	$16.33M	0.44%	―
JDOC	―	―	$8.78M	0.65%	―

Performance Comparison

BMED

Future Health ETF

31.08

4.57

17.24%

FMED

Fidelity Disruptive Medicine ETF

―

MEDI

Harbor Health Care ETF

―

MEDX

Horizon Kinetics Medical ETF

―

TMED

T. Rowe Price Health Care ETF

―

JDOC

JPMorgan Healthcare Leaders ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents